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Abstract
MicroRNAs are small non-coding RNA molecules that regulate mRNA translation and stability by binding to complementary
sequences usually within the 39 un-translated region (UTR). We have previously shown that the hepatic toxicity caused by
wild-type Adenovirus 5 (Ad5WT) in mice can be prevented by incorporating 4 binding sites for the liver-specific microRNA,
mir122, into the 39 UTR of E1A mRNA. This virus, termed Ad5mir122, is a promising virotherapy candidate and causes no
obvious liver pathology. Herein we show that Ad5mir122 maintains wild-type lytic activity in cancer cells not expressing
mir122 and assess any effects of possible mir122 depletion in host cells. Repeat administration of 2610
10 viral particles of
Admir122 to HepG2 tumour bearing mice showed significant anti-cancer efficacy. RT-QPCR showed that E1A mRNA was
down-regulated 29-fold in liver when compared to Ad5WT. Western blot for E1A confirmed that all protein variants were
knocked down. RT-QPCR for mature mir122 in infected livers showed that quantity of mir122 remained unaffected. Genome
wide mRNA microarray profiling of infected livers showed that although the transcript level of .3900 different mRNAs
changed more than 2-fold following Ad5WT infection, less than 600 were changed by Ad5mir122. These were then filtered
to select mRNAs that were only altered by Ad5mir122 and the remaining 21 mRNAs were compared to predicted mir122
targets. No mir122 target mRNAs were affected by Ad5 mir122. These results demonstrate that the exploitation of microRNA
regulation to control virus replication does not necessarily affect the level of the microRNA or the endogenous mRNA
targets.
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Introduction
Genetic regulation of virus replication and expression is a
powerful strategy for the development of safer viral therapeutics
for vaccination, gene therapy and virotherapy. DNA viruses are
often made tissue or cancer selective by the replacement of strong
viral promoters with weaker human endogenous promoters. In
contrast, mechanisms for the control of RNA virus replication
have largely focussed on engineering or exploiting interferon
sensitivity [1,2] or using attenuated vaccine strains [3]. No
universal mechanism of control for all viruses or viral transgenes
has proven successful. However, the discovery of the microRNA
regulatory network has allowed the design of viral vectors in which
essential mRNAs are selectively degraded in tissues expressing a
specific microRNA, affording the possibility of control through
tissue-selective inactivation of essential viral functions.
MicroRNAs are non-coding RNA molecules that negatively
regulate mRNA translation through binding to sequences usually
found within the 39 un-translated region (UTR) [4]. The level of
complementarity between the microRNA and the target influences
whether the mRNA is degraded (perfect complementarity) or
forms a stable translationally inactive complex. The inclusion of
microRNA binding sites into the 39UTR of mRNAs encoding
essential viral proteins allows the selective destruction of the
mRNA and prevents protein translation. The pre-requisite of all
viruses to exploit mRNA translation in order to replicate means
that this method of control can be universally applied to every
virus infecting a eukaryotic cell.
Examples in which the technique has been used successfully are
in the control the of replication of Polio virus [5], Herpesvirus [6],
Vesicular Stomatitis virus [7,8], Influenza virus [9] and Adeno-
virus type 5 (Ad5) [10,11]. Viral vectors in which this technique
has been successfully used to control transgene expression include
Dengue virus replicons [12], Alphaviral replicons [13], Lentiviral
vectors [14] and Adenoviral vectors [15]. Based on current
literature, it is clear that the virus type, the microRNA of choice
and the tissue of pathology are all important in defining the level to
which a virus is successfully controlled.
Ad5 has been extensively investigated in the context of
virotherapy and the wild type strain (Ad5WT) has been shown to
have potent anticancer activity [16]. However, following intrave-
nous administration to mice, Ad5WT causes acute hepatic toxicity
which, at doses above 1x10
9 pfu, is uniformly fatal [17]. This
toxicity is believed to reflect high levels of expression of the E1A
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downstream viral gene expression and hepatocyte cell death.
To abrogate this toxicity, without affecting viral replication in
cancer cells, we inserted four perfectly complementary binding
sites for the hepatocyte-specific microRNA mir122 into the 39
UTR of the E1A transcription cassette (a virus termed Ad5-
mir122). The perfect complementarity between the mir122
binding sites we have inserted and microRNA mir122 should
result in substantial E1A mRNA cleavage through a mechanism
similar to RNAi. We have shown previously that this can reduce
hepatic viral replication, ALT release and liver pathology [10].
Little is known about the potential unwanted cellular conse-
quences of the control of viruses using microRNA binding sites.
The amount of cellular microRNA could be decreased by the
addition of viral target mRNAs or the viral mRNAs could saturate
the activity of the microRNA and allow changes in the levels of
endogenous mRNA targets. Previous studies using microRNA
regulated lentiviral vectors have shown that this can occur when
cells are exposed to a high multiplicity of infection. This suggests
that the regulatory effect of microRNAs are saturable at high doses
[20]. Below this threshold the microRNA endogenous mRNA
targets are reported to remain unchanged [21]. In this study we set
out to determine whether the dose of Ad5mir122 capable of
showing intravenous efficacy in treating cancer would significantly
affect hepatic levels of mir122 or its mRNA targets.
Materials and Methods
Adenovirus preparations
Adenovirus cloning has been described previously [10]. All
adenoviruses were grown in A549 cells, purified by double banding
in CsCl gradients with benzonase treatment after the first banding.
Viral particle (vp) number was determined by measuring DNA
content using a modified version of the PicoGreenassay (Invitrogen,
Paisley, UK) [22]. TCID50 calculated with the KA ¨RBER statistical
method [23] was used to estimate the adenovirus titer (TCID50
units/ml)and corrected todetermineplaqueformingunits/ml(pfu/
ml). Adenovirus preparation characteristics are as follows: Ad5WT:
1.13610
12 vp/ml, 1.98610
11 pfu/ml and particle:infectivity (P:I)
ratio of 5.6; Ad5mir122: 1.29610
12 vp/ml, 2.01610
11 pfu/ml and
particle:infectivity (P:I) ratio of 6.4.
Maintenance of cell lines
HT29-Luc and Lovo-Luc colorectal cell lines were obtained
from Caliper Life Sciences (Runcorn, UK). Human hepatocellular
carcinoma HepG2 and Hep3b cell lines and A549 lung carcinoma
cells were obtained from the European Collection of Cell Cultures
(Porton Down, UK), and maintained in DMEM with 10% foetal
bovine serum (FBS) (PAA Laboratories, Yeovil, UK) including
penicillin (25 U/ml) and streptomycin (10 mg/ml).
Luciferase assays
Cells were seeded in triplicate in 48 well plates at 2.5610
4 cells/
well. Virus infections were performed at 10 vp/cell. 24 hrs
following infection the media was removed and 150 ml reporter
cell lysis buffer (Promega) was added. Cells were frozen at 280uC
for 1 hr before thawing. Luciferin (25 ml) (Promega, Southampton,
UK) was added to 25 ml of cell lysate and relative luminescence
was measured by luminometry (Lumat LB 9507, Berthold
Technologies, Redbourn, UK).
MTS Assays
Cell viability was determined using the CellTiter 96 Aqueuos
One Solution Cell Proliferation Assay (Promega). Cells were
seeded at 1610
4/well in 96 well plates in 100 ml media. After
24 hours, viruses were added at 10 and 100 vp/cell in 100 ml
media. Cells were left for either 3 or 6 days. At each time point
media was removed and 20 ml MTS reagent in 180 ml media was
added and cells were incubated for 30 minutes. Plates were read at
490 nm for 0.1 seconds. Blank wells containing MTS reagent and
media but no cells served as background and non-infected cells
represent 100% survival in each cell type. N=5 for each assay.
Primary Hepatocyte culture
Frozen Human primary hepatocytes (NHeps, CC-2591), Hepa-
tocyte Basal medium HBM
TM(CC-3199), supplements and growth
factors HCM
TM SingleQuots (CC-4182) were purchased from
Lonza. Cells were seeded and manipulated according to Lonza’s
protocol. A 96 well plate was coated with rat tail collagen type 1
(Sigma, C3867)at 60 mg/cm
2. Cells were thawed at 37uC ina water
bath, centrifuged at 4uC for 3 minutes at 50 g and then washed in
cold culture medium. Cells were re-suspended and the number and
viability was confirmed using the Trypan blue dye exclusion
method. The viability obtained was 60% at seeding. Cells were
seeded at 5610
4/well with 120 ml medium each well. The medium
was changed at 3 hours after seeding. Virus infections were
performed 24 hrs after seeding in 100 ml fresh medium at 1 vp/
cell, another 100 ml medium was added at 2 hrs post-infection.
100 ml of media was exchanged each day and until experiment
completion (72 hrs). The supernatant was removed by aspiration
and cells were lysed in 100 ml Promega reporter lysis buffer (E397A)
and frozen at 280uC before luciferase quantitation.
Western Blots
Protein was extracted from murine liver by homogenisation in
Promega lysis solution at 80 mg/ml wet weight. Samples were
span at 2000 rpm for 5 minutes at 4uC to remove cell debris. 30 mg
of liver protein was loaded onto a 10% polyacrylamide gel after
quantitation using a QuantiPro BCA assay (Sigma Aldrich, cat:
QPBCA-1KT). The gel was run at 160V for 1 hr and then protein
was blotted to a nitrocellulose membrane overnight at 4uC at 30V.
Nitrocellulose membrane was stained with Ponceau solution to
confirm equal loading (data not shown) and then blocked using 5%
milk powder (Fluka, Sigma Aldrich) for 2 hrs (E1A) or overnight
(Aldolase A). Membrane was washed twice with PBS 0.1% Tween
20 and then once with PBS. For the E1A western blot, primary
antibody recognising E1A (AbCam, Cambridge, UK, cat number:
Ab33183) was added at 1:500 dilution in 2.5% milk powder in
PBS for 1 hr. Membrane was washed as above. Secondary anti-
rabbit HRP labelled antibody was added at 1:1000 dilution in
2.5% milk powder for 1 hr. For the Aldolase A western blot,
primary antibody recognising Aldolase A (Sigma-Aldrich, cat
number: AV48130) was added at 1:1000 dilution in 2.5% milk
powder in PBS for 1 hour. Membrane was washed as above.
Secondary antibody was the same as used for Adenovirus E1A
western blot but used at a 1:4000 dilution for 1 hour. The
membranes were washed as above and then bathed in ECL
western blotting detection reagent (Amersham, GE Healthcare) at
0.125 ml/cm
2 for 1 minute. Blot was visualised in an Alpha
Innotech gel documentation system for 1, 5 and 10 minutes using
chemi-luminescence detection.
RNA extraction and Reverse-transcription quantitative
PCR for E1A mRNA
Total RNA from murine livers was extracted using mirVana
miRNA isolation kit (Ambion) without the miRNA enrichment
step. Reactions were performed using TaqMan RNA-to-CT 1-step
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PCR cycles were as follows: 95uC 10 minutes, then 40 cycles at
95uC 15 seconds, 60uC 1 minute. Primer sequences for targeting
E1A 13S were: Fwd – ATG TTT GTC TAC AGT CCT GTG
TCT GAA, Rev – GAT AGC AGG CGC CAT TTT AGG and
probe – CCA GAA CCG GAG CCT GCA AGA CCT AC
(Sigma-Aldrich), dual labeled at the 59 end with 6-carboxyfluor-
escein and the 39 end with 6-carboxytetramethylrhodamine.
Results were analysed with StepOne Plus Real-Time PCR
Systems software (Applied Biosystems). Standard curves were
made by serial dilutions of known quantities of E1A DNA using an
Ad5 E1A encoding plasmid and assumes 100% extraction
efficiency.
Animal Models
Nu/nu CD1 female mice were obtained from Charles Rivers
Laboratories at 4–6 weeks old. 5610
6 HepG2 cells were injected
subcutaneously. Mice were randomised prior to treatment. Initial
tumour sizes were typically 10–20 mm
3. All were pre-treated with
bisphosphonate liposomes (100 ı `l/mouse, obtained from Dr Nico
van Rouijen) 24 h before the first dose of virus. In the study of
intravenous efficacy mice received bisphosphonate liposomes twice
at days -1 and 18. All control animals received this treatment. 10
Animals were used in each group.
Tumour sizing and Kaplan Meier analysis
Tumour volume was measured using hand-held callipers and is
defined as the size of the largest tumour in each mouse. Tumour
volume is calculated as an ellipsoid [24]. Kaplan Meier analysis
was performed using Prism software and is shown as the
percentage group survival at each time point.
Imaging
In vivo virus activity was assessed by non-invasive luciferase
imaging using an IVIS 100 system (Xenogen, MA). D-Luciferin
(potassium salt) (Gold Biotechnology inc) was prepared in PBS at
15.8 mg/ml. 100 ml Luciferin was administered via intra-perito-
neal injection and mice were imaged 4 minutes later.
Measurement of Serum Alanine Aminotransferase (ALT)
50 ml blood was taken from mice by tail bleed and allowed to
clot (15 min, room temperature) and spun at 1200 g for 10 min.
Serum was isolated and immediately frozen at 220uC. Samples of
thawed serum (5 ml) were added to ALT reagent (995 ml,
Microgenics) in a 1 ml quartz cuvette, incubated at 37uC and
the change in absorbance (340 nm) per minute was measured.
Units of ALT per litre were calculated according to the
manufacturer’s instructions using the following equation: Activity
in Units/Litre =A ¨ Absorbance change per minute x factor (factor
= total reaction volume 6 1000/6.3 6 sample volume 6 path
length).
MicroRNA Quantitation
RNA was extracted from murine liver as described above and
was diluted to 1 ng/ml in nuclease free water. Mature mir122
levels were quantified using a TaqMan MicroRNA Assay (Applied
Biosystems) specific for mir122 (Part number: 4427975 Assay ID:
002130). Briefly, Reverse transcription (RT) reactions (15 ml) were
set up according to manufacturer’s guidelines to using Multiscribe
Reverse Transcriptase (50U/reaction), dNTPs (1 mM final
concentration), 0.188 ml RNase inhibitor, 1.5 ml 10X RT buffer,
3 ml 5X mir122 TaqMan MicroRNA RT primer and 5 ml RNA
sample (1 ng/ml). Reaction conditions were 30 minutes 16uC, 30
minutes 42uC, 5 minutes 4uC. cDNA (1.33 ml of RT reaction) was
added to 1 ml 20X Mir122 Taqman MicroRNA Assay, 10 ml
TaqMan 2X Universal PCR master mix and made up to 20 ml
using nuclease free water. Real-time PCR conditions were 10
minutes at 95uC, followed by 40 cycles of 15 seconds at 95uC then
1 minute at 60uC. Samples were run on a Step One Plus real-time
PCR system (Applied Biosystems). The microRNA let7a was used
as an internal standard using the conditions described above and
using the TaqMan MicroRNA Assay (Applied Biosystems) specific
for mature let7a RNA (Part number: 4427975 Assay ID: 000377).
Relative standard curves were produced by ten-fold serial dilutions
of liver RNA extracted from a mouse receiving PBS. Reaction
properties were as follows; mir122 assay: slope 3.28, 101.78%,
efficiency 2.02 and Let 7a assay slope 3.268, 102.29%, efficiency
2.01. Relative expressions were calculated using the method
published by Pfaffl, M [25]. Probes were labeled at the 59 end with
6-carboxyfluorescein and at the 39 end with a non-fluorescent
quencher coupled to a minor groove binder (MGB).
mRNA microarray analysis
RNA was extracted from murine liver as described above. Each
group contains 3 mice and independent chips were used for
each sample. Whole-genome gene expression analysis were
performed using Illumina Single Colour Mouse WG-6_V2_0_R0_
11278593_A BeadChip with direct hybridization assay (Illumina,
Essex, UK) according to the manufacturer’s directions starting
with 300 ng total RNA from each sample. Biotinylated cRNA was
prepared using the Illumina TotalPrep-96 RNA Amplification Kit
(# 4393543 Ambion, Inc., Austin, TX). This briefly includes a
first- and second-strand reverse transcription step, followed by a
single in vitro transcription (IVT) amplification that incorporates
biotin-labelled nucleotides. Subsequent steps include array hy-
bridization, washing, blocking, and streptavadin-Cy3 staining.
Fluorescence emissions by Cy3 were quantitatively detected by
BeadArray Scanner for downstream analysis. GenomeStudio Data
Analysis Software was used to Visualize and analyze data
generated. This software provides results in standard file formats
that can be readily processed with most commercial expression-
analysis software programs. Data was imported to GeneSpring
GX 11.0.2 (Agilent Technologies, Inc, Santa Clara CA)
normalized with Shift to 75 percentile and baseline transformed
to median of all samples for detailed analysis to identify
significantly differentially expressed genes. The data discussed in
this publication is MIAME compliant and have been deposited in
NCBI’s Gene Expression Omnibus [26] and are accessible
through GEO Series accession number GSE23854 (http://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE23854).
Ethics Statement
All animal experimentation was performed in accordance with
the terms of UK Home Office guidelines and the UKCCCR
Guidelines for the Welfare of Animals in Experimental Neoplasia.
The home office project license number under which these
experiments were conducted is PPL 30/2333. All experiments
were conducted with approval of the Medical Sciences Animal
Ethics Committee, University of Oxford.
Results
Ad5mir122 shows decreased E1A expression in primary
human hepatocytes
We have previously shown that the inclusion of microRNA
binding sites within the 39UTR of adenovirus E1A mRNA leads to
lower E1A protein in both murine liver in vivo and in the mir122
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cells express only 8% of the mir122 levels of primary human
hepatocytes [27]. We therefore wanted to measure the level of
control of viral transgene expression that could be achieved in
primary human hepatocytes as a surrogate for human liver.
Primary human hepatocytes (1610
4/well) were incubated with
either Ad5WT encoding luciferase C-terminally fused to the E1A
protein (Ad5WTLuc) or the equivalent virus containing four
mir122 binding sites in the E1A-luciferase 39UTR (Ad5mir122-
luc). After 72 hours the luciferase levels were .30-fold lower in
cells infected with Ad5mir122luc (9.5610
2 RLU/mg) when
compared to Ad5WTluc (2.7610
4 RLU/mg) (Figure 1). This is
the first demonstration of control of a microRNA regulated virus
in primary human cells and highlights the potential clinical utility
of exploiting microRNA regulation in therapeutic viruses.
Ad5mir122 kills mir122 negative cells with Ad5WT
potency
The ability of Ad5mir122 to kill tumour cells not expressing
mir122 was compared to Ad5WT. Multiple cell lines were
incubated at 10 and 100 vp/cell and the cell viability was
determined after 3 or 6 days by MTS assay. Equal cell killing was
observed with both viruses at both MOIs by day 3 (data not
shown). Almost complete cell killing in some cell lines was
observed at the higher MOI by day 6 (Figure 2). Interestingly, the
cell line most susceptible to killing by both viruses was HepG2
human hepatocellular carcinoma which is reported to be mir122
negative [27]. Given that decreases in mir122 levels in primary
hepatomas is an indicator of poor prognosis [28], HepG2 cells
represented a promising tumour model which should maximise
the therapeutic index achieved by Ad5mir122 between tumour
tissue and primary liver.
Pharmacodynamics-led determination of optimal virus
doses
The optimal doses of Ad5mir122 and Ad5WT were determined
in order to define a protocol that would allow repeat delivery in a
cancer efficacy model. Although we have previously defined the
single injection maximum tolerated dose in normal mice of
Admir122 (6610
10 vp), treatment of xenograft bearing nude mice
may require a different protocol, and therefore a pharmacody-
namics-led dose escalation study was performed.
Ad5WT and Ad5mir122 were administered intravenously to
CD1 nude mice bearing HepG2 xenografts, with serum ALT
measured after each dose (Figure 3a). The starting dose for both
viruses was 6610
9 vp/mouse, corresponding to 8.8610
8 pfu for
Ad5WT, slightly lower than the published maximum tolerated
dose (MTD, 1610
9 pfu) [17]. To enable imaging of virus activity
each dose contained 10% Ad5mir122luc.
Two days following administration of 6610
9 vp Ad5WT, mice
showed dramatically elevated ALT levels (.1000 Units/L)
suggesting significant hepatic toxicity (Figure 3a). Imaging showed
high levels of hepatic luciferase expression, confirming virus
activity in the liver with little to no tumour signal (Figure 3b).
Although the ALT values fell steadily over days 2–8 (Figure 3a),
several animals (6 out of 10) showed significant weight loss (.5%)
and one was put down (weight loss .15%). Accordingly this dose
of Ad5WT was taken as the MTD, and treatment was not
escalated.
In contrast, two days following administration of the same dose
(6610
9 vp) of Ad5mir122, mice showed ALT readings similar to
PBS controls (Figure 3a). Imaging data confirmed this result with
no detectable hepatic luciferase (Figure 3b). Little to no tumour
infection was observed with this dose.
The dose of Ad5mir122 was therefore increased by a half log to
2610
10 vp, three days after the first injection. Imaging at day five
showed some luciferase activity (indicating expression of E1A) in
both tumour and liver, although absolute values varied between
mice (data not shown). Average ALT values showed an increase to
222 ALT units/L compared to 42 ALT units/L from controls
(Figure 3a). On day six the dose was further increased by a half log
to 6610
10 vp. Imaging at day eight showed significant luciferase
activity in the tumours, however this was coupled with measurable
luciferase activity also in liver (Figure 3c). ALT readings showed
only a small increase from the previous dose (Figure 3a). This
study confirmed that 6610
10 vp of Ad5mir122 was close to the
MTD for Admir122, in agreement with our previous data in
normal mice.
Repeat administration of Adenovirus can cause cumulative
toxicity [10]. For assessment of efficacy it was desirable to
administer virus on multiple occasions, hence for repeated
administrations we selected dose levels that were half a log lower
than the estimated MTDs of Ad5mir122 (2610
10 vp/mouse) and
Ad5WT (2610
9 vp/mouse).
Efficacy of Ad5mir122 and Ad5WT in a hepatoma
xenograft model
To determine the anti-cancer activity of Ad5mir122, nude mice
bearing established HepG2 xenografts were administered 2610
10
vp intravenously on days 0, 3, 19 and 22 while control animals
received either 2610
9 vp of Ad5WT or PBS. Treatment began
with tumours between 10–20 mm
3 in size. Tumour growth was
monitored for efficacy and a survival endpoint (for the Kaplan
Meier graph) was introduced when individual tumour volume
reached 400 mm
3. Animals showing the fastest tumour growth
were allowed to continue beyond this point (up to 1000 mm
3)t o
allow the group average tumour size to reach 400 mm
3. Mice
administered Ad5mir122 showed significantly reduced tumour
volume from day 20 compared to PBS controls (Figure 4a).
However, mice receiving Ad5WT also demonstrated significant
anti-cancer efficacy. This is perhaps unsurprising given that
Figure 1. Ad5mir122 shows reduced E1A activity in primary
hepatocytes. Primary human hepatocytes were infected with either
Ad5mir122luc or Ad5WTluc at 1 vp/cell. Luciferase levels are shown 3
days post infection (n=3) as relative light units per mg total protein.
Error bars represent standard deviation.
doi:10.1371/journal.pone.0016152.g001
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is important to highlight that the doses of Ad5mir122 and Ad5WT
were not equitoxic. After 4 days in treatment with Ad5WT one
mouse was put down due to weight loss (.15%) and hepatic
toxicity (Figure 4b). No such adverse events occurred in the group
receiving Ad5mir122 at a 10-fold higher dose.
Kaplan Meier analysis of mice administered Ad5mir122 showed
increased survival with all mice surviving longer than all controls
Figure 2. Ad5mir122 kills mir122 negative cells with Ad5WT potency. Comparison of Ad5mir122 and Ad5WT in cancer cell lines incubated at
a multiplicity of infection of 100 viral particles per cell. The percentage cell survival is shown 6 days post infection (N=5) using an MTS cell survival
assay. Statistical analysis was performed using one way ANOVA (*=p,0.05, NS = not significant).
doi:10.1371/journal.pone.0016152.g002
Figure 3. Pharmacodynamics led dose escalation study to determine the optimal treatment dose with Ad5mir122 and Ad5WT in
tumour bearing mice. A) Serum Alanine Transaminase (ALT) levels from mice receiving Ad5mir122, Ad5WT or PBS. ALT values for each group are
shown at days 2, 5 and 8 (n=3) after the first injection. Data is presented as ALT units per litre using the equation in the materials and methods. B)
Luciferase imaging 2 days after the first injection of Ad5mir122 (left panel) or Ad5WT (right panel). C) Luciferase imaging eight days after the first
injection. Mice which received a single injection of Ad5WT are shown in the right panel and mice receiving three injections of Ad5mir122 are shown
in the left panel. Images are all presented on the same scale. D) Dosage and treatment schedule for Ad5mir122 and Ad5WT. Viral doses are indicated
above each line and include 10% of a Luciferase reporter virus (Ad5mir122luc). All mice were treated with bisphosphonate liposomes at day -1.
doi:10.1371/journal.pone.0016152.g003
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Ad5mir122 at doses above the MTD of Ad5WT can have
significant anti-cancer efficacy without toxicity.
Assessment of intra-hepatic Ad5mir122 E1A activity
To quantify both the E1A mRNA and protein produced by
Admir122 at the optimal treatment dose in comparison to
Ad5WT, Balb/C mice were injected with 2610
10 vp and the
livers were harvested after 48 hrs. As further controls mice were
administered PBS or an E1A deleted non-replicating adenovirus
type 5 encoding luciferase (AdLuc) at the same dose. RNA was
extracted and the major E1A 13S transcript was measured by RT-
QPCR. Ad5mir122 showed a 29-fold decrease in the level of 13S
E1A transcript copies when compared to Ad5WT. E1A mRNA
Figure 4. Ad5mir122 has potent anti-cancer efficacy in HepG2 tumour bearing mice. Repeat administration of Ad5mir122 (n=10 mice) at
the treatment dose determined from figure 2 (2610
10vp) on days 0, 3, 19 and 22 by intravenous injection. Control animals received repeat
administration of 2610
9 vp Ad5WT or PBS by intravenous injection (n=10 mice). A) Tumour volume of mice receiving PBS or Ad5mir122 or Ad5WT
was calculated as the volume of an ellipsoid [24]. Statistical analysis was performed using one way ANOVA with a Bonferroni post test (ns = not
significant, * =P,0.05, ** =P,0.01) at each time point. Error bars are shown as standard error. B) Kaplan Meier survival analysis shows increased
survival of mice receiving Ad5mir122 and Ad5WT compared to control mice receiving PBS. After 4 days in treatment with Ad5WT one mouse was put
down due to toxicity. No treatment related toxicities were observed during Ad5mir122 treatment or treatment with PBS. Days shown on both of the
horizontal axis represent the number days since the first virus injection.
doi:10.1371/journal.pone.0016152.g004
Figure 5. MicroRNA mediated knockdown of both E1A mRNA and protein measured by RT-QPCR and western blot after
intravenous injection of 2610
10 vp of Ad5mir122. A) RT QPCR for the 13S E1A mRNA transcript in the livers of mice 48 hrs after intravenous
injection with 2610
10 vp of Ad5mir122, Ad5WT, Ad5Luc or PBS. Ad5mir122 shows significantly reduced E1A mRNA during liver infection when
compared to Ad5WT (N=3). Statistical analysis was performed using a two tailed student T-Test (*P=,0.05). B) Western blot to confirm that all E1A
proteins variants are knocked down. Each lane represents protein extracted from an individual mouse. Control lanes containing liver from mice
treated with either an E1A deleted Ad5Luc vector or PBS show no E1A signal. Ad5WT treatment shows 3 clearly defined bands corresponding to
proteins produced from the 13S (36 kDa), 12S (26 kDa) and a smaller fainter band which may represent the 11S or the 10S E1A transcript product.
Treatment with Admir122 shows significant knockdown in E1A protein levels for all splice variants. The blot was exposed for 1, 5 and 10 minutes with
the 5 minute exposure presented here. Molecular weights were calculated against a dual colour molecular weight ladder (Bio-Rad).
doi:10.1371/journal.pone.0016152.g005
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6 and 1.54610
5,
respectively. This confirmed that the stability of the mRNA is itself
directly affected by microRNA regulation, as would be expected
(Figure 5a).
To confirm that the reduced level of E1A mRNA resulted in
decreased E1A protein production, and to confirm that the effect
was not E1A 13S specific, liver protein extracts were analysed by
western blot for E1A protein. Figure 5b shows that whilst infection
with Ad5WT resulted in significant E1A protein production,
infection with Ad5mir122 resulted in almost undetectable levels.
The major species of E1A protein correlating with the 36 kDa
(13S) and 26 kDa (12S) proteins are clearly visible with a smaller
band which may represent the protein product of the 10S or 11S
mRNA. No E1A signals were detected in control mice receiving
PBS or a non-replicating E1A deleted AdLuc vector. Equal
protein loading and blot transfer were confirmed by Ponceau
staining (data not shown).
Mir122 levels remain unaffected by Ad5mir122 infection
The production of E1A mRNA within hepatocytes that contains
multiple microRNA binding sites could lead to the sequestration of
mir122 away from its endogenous mRNA targets or depletion of
the total mir122 content in the cell. The livers screened in figure 5
by E1A western blot and RT-QPCR were analysed to determine
the quantity of mature mir122 RNA. All results were standardised
against the highly abundant microRNA let7a which should be
unaffected by Admir122 treatment. Comparative analysis of the
level of mir122 found in mice treated with Ad5WT, Ad5mir122 or
Ad5luc showed that there was no difference in the levels of mir122
following any virus administration when compared to the level of
mir122 in mice administered PBS (Figure 6a). The ratio of mir122
levels in mice administered Ad5WT, Admir122 and Ad5luc when
compared to the amount in mice receiving PBS were 1.04
(60.188), 1.06 (60.163) and 1.14 (60.14), respectively. This
proved that the level of mir122 was unaffected by the presence of
Ad5mir122 infection however it did not confirm if mir122 was
being sequestered away from its endogenous mRNA targets by
direct competition.
Ad5mir122 reduces genome wide hepatocyte mRNA
changes
Microarray genome wide mRNA profiling was performed on
livers of mice 48 hrs after the injection of either 2610
10 vp of
Ad5mir122, Ad5WT, an E1A deleted non-replicating AdLuc
vector or PBS. This assessment allowed the quantitation of mRNA
changes due to microRNA regulation of Ad5mir122 but also
served to highlight any mRNA differences between Ad5mir122
and Ad5WT. The maximum change observed in any mRNA was
111-fold although any mRNA profile change greater than 2-fold
was considered significant and highlighted for further analysis.
Data from the three independent animals was remarkably
consistent and can be viewed at the NCBI’s Gene Expression
Omnibus database. The most striking result between the different
viruses was the total number of mRNAs changed. Whilst Ad5WT
altered 3946 mRNAs $ 2-fold, Ad5mir122 altered only 668
mRNAs (Figure 6b). The E1A deleted AdLuc vector altered a total
of 564 mRNAs $2-fold. This shows that the technique can detect
many changes of varying magnitude but that infection of murine
liver with Ad5mir122 causes significantly fewer intracellular
changes than infection with Ad5WT.
The presence of additional microRNA regulated mRNA could
lead to sequestration of mir122 molecules away from their
endogenous targets. Therefore, any mRNA change observed
between mice administered PBS and Ad5mir122 that was not
shared between Ad5mir122 and either Ad5WT or AdLuc were
considered Ad5mir122 specific and were investigated further.
These mRNAs, which numbered only 21 in total (Table 1), were
Figure 6. The level and activity of mature mir122 in vivo is
unaffected by Ad5mir122. Mice were injected with 2610
10 vp of
either Ad5mir122, Ad5WT, an E1A deleted Ad5luc vector or PBS.
Quantification of mir122 mature RNA levels was performed using a
Taqman microRNA assay specific for mir122. CT values were corrected
against the levels of the microRNA, let7a, as a reference gene using the
method published by Pfaffl M [25]. A) RT-QPCR for mir122 showing nine
superimposed amplification curves (from three mice) in each treatment
group, before correction against let7a. Samples were reverse tran-
scribed using equal amounts of total RNA (5 ng) and RT-PCR was
performed using equal amounts of cDNA. CT values shown here
represent the average of the reactions from three mice plus or minus
standard deviation. B) The total number of mRNA changes recorded by
genome wide mRNA profiling of extracted murine hepatic RNA. Positive
signals are those in which the median mRNA level changed by P2-fold
from all mice in each group in comparison to median mRNA level in
mice treated with PBS (n=3 for all groups). The total number of genes
altered is calculated using the average of the three independent
replicates and therefore no error bars are shown. C) Western blot
analysis of the mir122 regulated protein Aldolase A in mice treated as
above. Liver protein extracts were subjected to a BCA protein assay and
equal loading was confirmed by Ponceau stain (data not shown).
doi:10.1371/journal.pone.0016152.g006
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European Bioinformatics Institutes (EBI) Microcosm database. No
transcripts were predicted to contain mir122 binding sites. The list
of mir122 microcosm predicted targets was then compared to all
the signals from the microarray profiling to make sure no
important signals had been omitted by filtering the results as
described above. 143 predicted mir122 targets were altered in the
microarray analysis. Of those 143 mRNAs, 108 were altered only
by Ad5WT, 20 were shared by Ad5mir122 and Ad5WT but were
altered to the same extent and in the same direction (up- or down-
regulated). The remaining signals showed AdLuc specific changes.
This data shows that during the window of initial infection with
Admir122 the presence of microRNA regulated viral mRNA does
not alter the level of the endogenous microRNA mRNA targets.
Mir122 regulated Adolase A levels remain unaffected by
Ad5mir122
Although no differences had been observed in the levels of
known mir122 regulated mRNAs it was unclear if the quantity of
protein produced from these transcripts was altered. MicroRNA
suppression has been shown to decrease the protein level produced
from some mRNAs without changing the mRNA steady state
levels [30]. Therefore, mice were injected with 2610
10 vp of
Ad5mir122, Ad5WT, AdLuc or PBS. After 72 hours livers were
analysed by western blot for the levels of Aldolase A protein, a
known mir122 target [31,32]. Inhibition of mir122 function is
known to increase Aldolase A protein levels although the western
blot showed no difference between mice in the different treatment
groups (Figure 6c). This data suggests that mir122 regulation of
Aldolase A is maintained despite the presence of Ad5mir122 at
therapeutic doses.
Discussion
MicroRNA regulation of viral gene expression and replication
exploits the negative regulatory principle of microRNA mRNA
degradation. The success of this approach is reflected in the
number of RNA viruses for which it has already proven successful
[5,7,8,33,34]. In creating a DNA virus which was microRNA
regulated we anticipated that the level of control would be less
efficient and potentially more toxic by interfering with the
microRNA regulation of endogenous mRNA targets. This was
expected because the viral genome itself is not directly destroyed
when using a DNA virus and therefore continually produces
microRNA targeted viral mRNA. This could lead to sequestration
of the microRNA away from its endogenous mRNA targets and
alter the expression patterns of many genes.
Table 1. mRNAs in which the level was changed P2-fold by Ad5mir122 infection.
Gene Symbol
Compared to
PBS
Compared to
Ad Luc
Compared to
Ad5 WT Gene Name Accession
LOC381748 4.9 Q 5.6 Q 2.7 Q XM_355738.1
2310016F22Rik 4.6 Q 5.2 Q 2.6 Q RIKEN cDNA 2310016F22 gene
(2310016F22Rik)
NM_173743.2
Irf1 4.3 Q 5.0 Q 2.3 Q Interferon regulatory factor 1 (Irf1) NM_008390.1
Trim21 3.8 Q 4.2 Q 2.2 Q NM_009277.2
A630097K09Rik 3.5 Q 3.7 Q 2.5 Q AK042505
C2ta 3.4 Q 3.3 Q 2.2 Q AK040723
LOC435565 3.4 Q 5.2 Q 2.4 Q Similar to interferon-inducible GTPase
(LOC435565)
NM_001013828.1
Trim34 3.1 Q 3.4 Q 2.2 Q Tripartite motif protein 34 (Trim34) NM_030684.1
Tapbpl 3.1 Q 3.3 Q 2.1 Q TAP binding protein-like (Tapbpl) NM_145391.1
Trim34 3.0 Q 3.3 Q 2.0 Q Tripartite motif protein 34 (Trim34) NM_030684.1
Iigp-pending 2.9 Q 3.4 Q 2.0 Q AK089702
H2-T23 2.8 Q 3.5 Q 2.1 Q Histocompatibility 2, T region locus 23
(H2-T23)
NM_010398.1
Scotin 2.6 Q 2.8 Q 2.2 Q Scotin gene (Scotin), transcript variant 2 NM_026381.1
Saa1 2.4 Q 2.5 Q 2.0 Q NM_009117.1
EG240327 2.4 Q 2.8 Q 2.4 Q Predicted gene, EG240327 (EG240327) NM_001033767.1
LOC280487 2.3 q 2.1 q 3.6 q XM_203701.3
1200013B22Rik 2.3 Q 3.0 Q 2.2 Q NUAK family, SNF1-like kinase, 2 (Nuak2) NM_028778.2
Tapbp 2.2 Q 3.0 Q 2.9 Q TAP binding protein (Tapbp), transcript
variant 1
NM_001025313.1
0710001B24Rik 2.1 Q 3.0 Q 2.0 Q NM_175118
LOC244882 2.1 Q 2.2 Q 2.2 Q XM_146997.2
Tnfaip8l3 2.0 Q 2.0 Q 2.1 Q Tumor necrosis factor, alpha-induced protein
8-like 3 (Tnfaip8l3)
NM_001033535.1
Total mRNA profiling produced 4562 signals in which the mRNA levels were altered P2-fold after administration of either 2610
10 vp of Ad5WT, Ad5mir122, an Ad5luc
control vector or injected with PBS. The mRNAs in this table are those that show at least a 2-fold change in quantity following Ad5mir122 infection that are not altered
when compared to mice administered PBS, Ad5luc or Ad5WT. Mir122 predicted target mRNAs (produced using the Microcosm database) were compared to this list but
no positive matches were found.
doi:10.1371/journal.pone.0016152.t001
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complementary binding sites for hepatic specific microRNA
mir122 into the 39 UTR of adenovirus E1A allows efficient
mir122-controlled expression of E1A in murine liver, confirmed
by RT-QPCR and western blotting. We have demonstrated that
both the quantity of the microRNA and the stability of microRNA
targeted mRNAs are unaffected by Ad5mir122. Both of these
results are important toxicological findings and increase our
understanding of the safety profile of microRNA regulation.
Interestingly, the genome wide profiling of the mRNA levels in
livers infected with Ad5mir122 produced 21 mRNAs that were
altered P2-fold but it was not clear that they were directly
regulated by mir122. These signals may represent experimental
noise, however, given the reproducibility of the signals in
comparison to all other treatment groups and the extent to which
they are altered (in some cases up to 5-fold) this seems unlikely.
Further investigation would be required in order to determine the
cause of these changes and the effects they may have on cell
function.
The data reported here suggests that the highly abundant
microRNA mir122 is capable of regulating more mRNA
transcripts than are regulated under normal conditions in
hepatocytes and that it is probably expressed in excess of its
regulatory requirements. This was an advantage in our studies as it
allowed tight regulation of adenoviral E1A without altering
endogenous mRNA levels. However, other microRNAs may not
be as successful at controlling additional mRNA, especially if they
are expressed at lower quantities. The direct competition for
microRNA-mRNA binding between endogenous and exogenous
viral mRNA could result in changes in protein expression if the
quantity of the microRNA required for normal regulation was
only just met by its expression level. It has been shown that
significant alterations to the microRNA machinery can have toxic
side effects, usually by interfering with total microRNA production
[35] (i.e. DICER or RISC processing). Given that microRNAs do
not appear to have any obvious feedback mechanism to report the
addition of new target mRNA molecules, it seems unlikely that
increasing the quantity of mRNA target, as was done in this study,
for a single microRNA will cause such broad toxicity.
Within this paper we have also shown that the intravenous
administration of repeat doses of Ad5mir122 mediates anticancer
activity with negligible toxicity. All animals receiving Ad5mir122
performed better than all controls. This is the first anti-cancer
efficacy reported using a microRNA regulated oncolytic DNA
virus. Our data also builds on previously published evidence that
Ad5WT has potent anticancer efficacy [29], even at low doses.
However, as was clear in our studies, toxicity is a major limitation
to its use in animal models.
Genetic modification of adenoviruses to allow replication
selectively within tumour cells often relies on their activation by
cellular mechanisms, which can be weak compared to intrinsic
viral mechanisms. Accordingly such viruses, while providing good
safety, often show decreased anti-cancer potency compared to wild
type strains, particularly in vivo [29]. The exploitation of the
microRNA regulatory network is enabling the design of many new
viruses for cancer virotherapy, vaccination and gene therapy that
are modified to allow selective replication and expression only in
specific cell types and represents a new, safe and effective method
of controlling of viral gene expression.
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